Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Drug against breast cancer is also highly potent against a frequent form of leukaemia

17.05.2016

Acute myeloid leukaemia (AML) is the most frequent form of blood cancer. In about 30 percent of all AML patients, a mutation in the FLT3 tyrosine kinase accelerates the course of the disease. Common therapies were not successful in healing these patients so far. Researchers at the University of Veterinary Medicine, Vienna managed now to specifically target and kill AML cancer cells carrying this activating mutation. They used an agent that had recently been approved for breast cancer therapy. The study was published in the top hemato-oncology journal Blood.

Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body’s own safety mechanisms. To do so, cancer cells harbour mutations, which enable a continuous cellular growth.


Before treatment

Photo: Iris Uras/Vetmeduni Vienna


After treatment: The breast cancer treatment downregulates FLT3. The cancer cells die.

Photo: Iris Uras/Vetmeduni Vienna

In acute myeloid leukemia (AML), an activating mutation in the FLT3 tyrosine kinase is the most frequent mutation found in patients. According to first author Iris Uras from the Institute of Pharmacology and Toxicology at the Vetmeduni Vienna, these cancer cells depend on FLT3 – is FLT3 blocked, cancer cells die.

Common FLT3 inhibitors do not suffice to survive

Activation of signalling pathways caused by mutations in tyrosine kinases is involved in the pathogenesis of AML. Targeted pharmacological inhibition of such mutant genes holds great therapeutic potential in AML.

Because of the clinical importance of FLT3-mutations in disease progression in AML, there have been considerable efforts to develop FLT3 inhibitors which block the kinase activity and subsequently shall impair cell growth. Yet the initial great hopes have not been fulfilled and the clinical impact of FLT3 kinase inhibitors is limited. Responses in patients with FLT3 mutations have been transient and resistant clones have emerged rapidly.

Breast cancer therapeutic blocks the production of the FLT3 gene

In her study, Uras uncovered a novel therapeutic approach to treat patients with AML with FLT3 mutations. She found that another tumor-promoting factor, the enzyme CDK6, directly regulates and initiates the production of FLT3 and thus cause the disease.

The active agent developed for breast cancer treatment blocks the activity of CDK6 and subsequently downregulates FLT3. “We found a novel therapeutic window that attacks the dependency of a cancer cell on its growth regulator “, said Uras. The compound from breast cancer therapy deprives the cancer cells of “nutrients”. AML cancer cells carrying the mutation died immediately in the experiments. The drug does not affect cells lacking the mutation proving to be highly specific.

Active agent already approved

The advantage of having this agent at hand is the fact that it has already been approved for the therapy of breast cancer in 2015 – it significantly enhanced the lifespan of patients with breast cancer. Hence, clinical studies can be rapidly initiated without passing a long series of tests in advance.

A combination with compounds that block FLT3 kinase activity increases the efficacy of the breast cancer drug. The driver of the disease and as a consequence the continuous cell growth is suppressed. “We are attacking FLT3 from two sides there – blocking its expression and inhibiting its activity. A combination therapy could be a breakthrough for many patients suffering from leukaemia,” explained Uras.

About acute myeloid leukaemia

Leukaemia, also known as blood cancer, is a hematopoietic malignancy. The most frequent form is AML, acute myeloid leukaemia. Patients with AML have poor prognosis and high mortality rate despite considerable advances in chemotherapy and hematopoietic stem cell transplantations.

Service
The article „Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6“ by Iris Uras, Gina Walter, Ruth Scheicher, Florian Bellutti, Michaela Prchal-Murphy, Anca S. Tigan, Peter Valent, Florian H. Heidel, Stefan Kubicek, Claudia Scholl, Stefan Fröhling and Veronika Sexl was published in Journal Blood.
DOI: ´http://dx.doi.org/10.1182/blood-2015-11-683581
http://www.bloodjournal.org/content/early/2016/04/20/blood-2015-11-683581?sso-ch...

About the University of Veterinary Medicine, Vienna
The University of Veterinary Medicine, Vienna in Austria is one of the leading academic and research institutions in the field of Veterinary Sciences in Europe. About 1,300 employees and 2,300 students work on the campus in the north of Vienna which also houses five university clinics and various research sites. Outside of Vienna the university operates Teaching and Research Farms. http://www.vetmeduni.ac.at

Scientific Contact:
Iris Uras
Institute of Pharmacology and Toxicology
University of Veterinary Medicine Vienna (Vetmeduni Vienna)
T +43 699 182 04 603
iris.uras@vetmeduni.ac.at

Released by:
Heike Hochhauser
Corporate Communications
University of Veterinary Medicine Vienna (Vetmeduni Vienna)
T +43 1 25077-1151
heike.hochhauser@vetmeduni.ac.at

Weitere Informationen:

http://www.vetmeduni.ac.at/en/infoservice/presseinformation/presseinformationen-...

Heike Hochhauser | Veterinärmedizinische Universität Wien

Weitere Nachrichten aus der Kategorie Biowissenschaften Chemie:

nachricht Molekulare Schere stabilisiert das Zell-Zytoskelett
24.06.2019 | Paul Scherrer Institut (PSI)

nachricht Mitten ins Herz
24.06.2019 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft

Alle Nachrichten aus der Kategorie: Biowissenschaften Chemie >>>

Die aktuellsten Pressemeldungen zum Suchbegriff Innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Partielle Mondfinsternis am 16./17. Juli 2019

Gemeinsame Pressemitteilung der Vereinigung der Sternfreunde (VdS) und des Hauses der Astronomie in Heidelberg - Wie im letzten Jahr findet auch 2019 eine in den späten Abendstunden in einer lauen Sommernacht gut zu beobachtende Mondfinsternis statt, und zwar in der Nacht vom 16. auf den 17. Juli. Die Finsternis ist zwar nur partiell - der Mond tritt also nicht vollständig in den Erdschatten ein - es ist aber für die nächsten Jahre die einzige gut sichtbare Mondfinsternis im deutschen Sprachraum.

Am Dienstagabend, den 16. Juli, wird ein kosmisches Schauspiel zu sehen sein: Der Vollmond taucht zu einem großen Teil in den Schatten der Erde ein, es findet...

Im Focus: Fraunhofer IDMT zeigt akustische Qualitätskontrolle auf der Fachmesse für Messtechnik »Sensor + Test 2019«

Das Ilmenauer Fraunhofer-Institut für Digitale Medientechnologie IDMT präsentiert vom 25. bis 27. Juni 2019 am Gemeinschaftsstand der Fraunhofer-Gesellschaft (Stand 5-248) seine neue Lösung zur berührungslosen, akustischen Qualitätskontrolle von Werkstücken und Bauteilen. Da die Prüfung zerstörungsfrei funktioniert, kann teurer Prüfschrott vermieden werden. Das Prüfverfahren wird derzeit gemeinsam mit verschiedenen Industriepartnern im praktischen Einsatz erfolgreich getestet und hat das Technology Readiness Level (TRL) 6 erreicht.

Maschinenausfälle, Fertigungsfehler und teuren Prüfschrott reduzieren

Im Focus: Fraunhofer IDMT demonstrates its method for acoustic quality inspection at »Sensor+Test 2019« in Nürnberg

From June 25th to 27th 2019, the Fraunhofer Institute for Digital Media Technology IDMT in Ilmenau (Germany) will be presenting a new solution for acoustic quality inspection allowing contact-free, non-destructive testing of manufactured parts and components. The method which has reached Technology Readiness Level 6 already, is currently being successfully tested in practical use together with a number of industrial partners.

Reducing machine downtime, manufacturing defects, and excessive scrap

Im Focus: Erfolgreiche Praxiserprobung: Bidirektionale Sensorik optimiert das Laserauftragschweißen

Die Qualität generativ gefertigter Bauteile steht und fällt nicht nur mit dem Fertigungsverfahren, sondern auch mit der Inline-Prozessregelung. Die Prozessregelung sorgt für einen sicheren Beschichtungsprozess, denn Abweichungen von der Soll-Geometrie werden sofort erkannt. Wie gut das mit einer bidirektionalen Sensorik bereits beim Laserauftragschweißen im Zusammenspiel mit einer kommerziellen Optik gelingt, demonstriert das Fraunhofer-Institut für Lasertechnik ILT auf der LASER World of PHOTONICS 2019 auf dem Messestand A2.431.

Das Fraunhofer ILT entwickelt optische Sensorik seit rund 10 Jahren gezielt für die Fertigungsmesstechnik. Dabei hat sich insbesondere die Sensorik mit der...

Im Focus: Successfully Tested in Praxis: Bidirectional Sensor Technology Optimizes Laser Material Deposition

The quality of additively manufactured components depends not only on the manufacturing process, but also on the inline process control. The process control ensures a reliable coating process because it detects deviations from the target geometry immediately. At LASER World of PHOTONICS 2019, the Fraunhofer Institute for Laser Technology ILT will be demonstrating how well bi-directional sensor technology can already be used for Laser Material Deposition (LMD) in combination with commercial optics at booth A2.431.

Fraunhofer ILT has been developing optical sensor technology specifically for production measurement technology for around 10 years. In particular, its »bd-1«...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

VideoLinks
Industrie & Wirtschaft
Veranstaltungen

Meeresleuchten, Klimawandel, Küstenmeere Afrikas – Spannende Vielfalt bei „Warnemünder Abenden 2019“

24.06.2019 | Veranstaltungen

Plastik: Mehr Kreislauf gegen die Krise gefordert

21.06.2019 | Veranstaltungen

Rittal und Innovo Cloud sind auf Supercomputing-Konferenz in Frankfurt vertreten

18.06.2019 | Veranstaltungen

VideoLinks
Wissenschaft & Forschung
Weitere VideoLinks im Überblick >>>
 
Aktuelle Beiträge

Molekulare Schere stabilisiert das Zell-Zytoskelett

24.06.2019 | Biowissenschaften Chemie

Neues „Intelligent Edge Data Center“ bringt Smart Industries auf nächstes Level

24.06.2019 | Unternehmensmeldung

Meeresleuchten, Klimawandel, Küstenmeere Afrikas – Spannende Vielfalt bei „Warnemünder Abenden 2019“

24.06.2019 | Veranstaltungsnachrichten

Weitere B2B-VideoLinks
IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics